. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Contemp Clin Trials. 2019 Aug 7;84:105820. doi: 10.1016/j.cct.2019.105820

Table 2.

Number of participants with diagnostic results in hereditary cancer genes by randomization arm

	UC (N/%) Total = 93	CES (N/%) Total = 93	P-value^d
CRCP related
P/LP variant(s)	5 (5.4%)	7^a (7.5%)	0.28
VUS(s)	15 (16.1%)	21^b (22.6%)	0.13
Non-CRCP^c related
P/LP variant(s)	5(5.4%)	3(3.2%)	0.77
VUS(s)	1(1.1%)	1(1.1%)	0.50

^a.

One CES participant was compound heterozygous for 2 CRCP related P variants in the MUTYH gene

^b.

One CES participant had three CRCP related VUS findings (two in APC and one in AXIN2); one ES participants had two CRCP related VUS findings (one in APC, one in PTCH1); one CES participant had one CRCP related P variant (MSH2) and one CRCP related VUS finding (PMS2).

^c.

Non-CRCP related findings were due to non-CRCP genes on the UC multi-gene panels, not considered as SFs

^d.

P-value based on one-sided two-sample test of proportions